{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:01:06Z","timestamp":1785164466088,"version":"3.55.0"},"reference-count":146,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Extramedullary disease (EMD)\u2014the proliferation of clonal plasma cells in soft tissues without direct bone connection\u2014represents one of the most challenging manifestations of multiple myeloma, associated with aggressive biology, treatment resistance, and poor outcomes. EMD is driven by distinct pathophysiologic mechanisms including downregulation of adhesion molecules, acquisition of high-risk cytogenetic abnormalities (del(17p), gain(1q)), activation of the RAS\u2013MAPK pathway, epigenetic dysregulation such as EZH2 upregulation, and remodeling of the immune microenvironment toward an immunosuppressive, T-cell-depleted phenotype. Conventional therapies, including anti-CD38-based regimens, yield limited efficacy in EMD, with pooled overall response rates of approximately 20% in triple-class-exposed relapsed\/refractory disease. T-cell-redirecting therapies have emerged as the most promising treatment strategy. Both chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have demonstrated clinically meaningful activity in soft tissue EMD, with CAR T-cell therapy providing the deepest and most durable responses, and dual-targeting bispecific combinations showing particularly encouraging efficacy. Central nervous system (CNS) myeloma, the most devastating form of EMD, has historically carried a dismal prognosis. Emerging retrospective data suggest that both CAR T-cell therapy and bispecific antibodies can achieve meaningful CNS responses with acceptable safety profiles, as part of multimodal approaches incorporating CNS-directed therapies. Despite these advances, EMD remains associated with inferior outcomes even in the immunotherapy era, underscoring the need for strategies targeting the immunosuppressive microenvironment, novel therapeutic approaches, and prospective EMD-focused clinical trials. This review provides a comprehensive overview of the biology, classification, and evolving treatment landscape of both non-CNS and CNS EMD in the era of T-cell-redirecting immunotherapy.<\/jats:p>","DOI":"10.3390\/cancers18152415","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:08:14Z","timestamp":1785161294000},"page":"2415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-8557","authenticated-orcid":false,"given":"Aimaz","family":"Afrough","sequence":"first","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-9960","authenticated-orcid":false,"given":"Christen M.","family":"Dillard","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Alsup","sequence":"additional","affiliation":[{"name":"Biomedical Engineering, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0789-8941","authenticated-orcid":false,"given":"Jimmy","family":"Lee","sequence":"additional","affiliation":[{"name":"Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4779-6905","authenticated-orcid":false,"given":"Aishwarya","family":"Sannareddy","sequence":"additional","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl R.","family":"Abraham","sequence":"additional","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Turer","sequence":"additional","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-6316","authenticated-orcid":false,"given":"Adeel M.","family":"Khan","sequence":"additional","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6937-0120","authenticated-orcid":false,"given":"Sean M.","family":"Taasan","sequence":"additional","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2780","authenticated-orcid":false,"given":"Abdel Kareem","family":"Azab","sequence":"additional","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"},{"name":"Biomedical Engineering, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud R.","family":"Gaballa","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: A systematic literature review","volume":"12","author":"Beksac","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ajh.70138","article-title":"Extramedullary Disease-Achilles Heel in Myeloma?","volume":"101","author":"Kumar","year":"2026","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.13383","article-title":"Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation","volume":"169","author":"Weinstock","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: Definition, disease assessment and treatment considerations","volume":"194","author":"Beksac","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood-2009-01-199281","article-title":"RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma","volume":"114","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","article-title":"P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma","volume":"124","author":"Azab","year":"2014","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","article-title":"3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma","volume":"73","author":"Muz","year":"2015","journal-title":"Biomaterials"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.tranon.2017.04.010","article-title":"Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma","volume":"10","author":"Muz","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.3324\/haematol.2018.194688","article-title":"PYK2\/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma","volume":"104","author":"Muz","year":"2019","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1038\/bcj.2014.82","article-title":"Hypoxia promotes stem cell-like phenotype in multiple myeloma cells","volume":"4","author":"Muz","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1541-7786.MCR-14-0028","article-title":"The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies","volume":"12","author":"Muz","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.13927","article-title":"A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma","volume":"173","author":"Muz","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1080\/10428194.2017.1319052","article-title":"Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance","volume":"58","author":"Muz","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1182\/blood-2010-06-292243","article-title":"Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion","volume":"117","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"011006","DOI":"10.1117\/1.3520571","article-title":"Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy","volume":"16","author":"Runnels","year":"2011","journal-title":"J. Biomed. Opt."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.12734","article-title":"PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance","volume":"165","author":"Azab","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2016.142190","article-title":"Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma","volume":"101","author":"Quan","year":"2016","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2015.09.005","article-title":"Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia","volume":"39","author":"Weisberg","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/ajh.25627","article-title":"Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma","volume":"94","author":"Ghobrial","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Kikuchi","year":"2009","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41598-021-03748-0","article-title":"Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival","volume":"12","author":"Hathi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjh.13382","article-title":"Development of extramedullary myeloma in the era of novel agents: No evidence of increased risk with lenalidomide-bortezomib combinations","volume":"169","author":"Varga","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/1078-0432.CCR-19-0694","article-title":"Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion","volume":"26","author":"Ryu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","article-title":"Beyond the marrow: Insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors","volume":"38","author":"Jelinek","year":"2024","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/bloodadvances.2025016619","article-title":"Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations","volume":"9","author":"Zanwar","year":"2025","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood-2004-04-1670","article-title":"Combined disruption of both the MEK\/ERK and the IL-6R\/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells","volume":"104","author":"Chatterjee","year":"2004","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Burroughs Garc\u00eca, J., Eufemiese, R.A., Storti, P., Sammarelli, G., Craviotto, L., Todaro, G., Toscani, D., Marchica, V., and Giuliani, N. (2021). Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets. Cells, 10.","DOI":"10.3390\/cells10061360"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.0007-1048.2002.03364.x","article-title":"Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma","volume":"116","author":"Iwasaki","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-024-01208-2","article-title":"Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma","volume":"15","author":"Bingham","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic Classification and Individualized Prognosis in Multiple Myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41408-024-01190-9","article-title":"Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma","volume":"14","author":"Nardi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00432-025-06223-9","article-title":"A comprehensive analysis of bone marrow-derived cytogenetic abnormalities in multiple myeloma patients with extramedullary disease","volume":"151","author":"Xu","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/genes5010108","article-title":"Mechanisms of base substitution mutagenesis in cancer genomes","volume":"5","author":"Bacolla","year":"2014","journal-title":"Genes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.1038\/s41598-019-43575-y","article-title":"Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells","volume":"9","author":"Yamazaki","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1038\/sj.onc.1208771","article-title":"The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype","volume":"24","author":"Croonquist","year":"2005","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1038\/bcj.2017.27","article-title":"Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control","volume":"7","author":"Pawlyn","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/1535-7163.MCT-15-0486","article-title":"EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes","volume":"15","author":"Hernando","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e2102718118","DOI":"10.1073\/pnas.2102718118","article-title":"EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner","volume":"118","author":"Bugide","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"155992","DOI":"10.1016\/j.prp.2025.155992","article-title":"EZH2 regulatory roles in cancer immunity and immunotherapy","volume":"270","author":"Mortezaee","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_54","unstructured":"U.S. Food and Drug Administration (2026, June 01). FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Li, Y., Wilson, A., Chrisochoidou, Y., Martin, S., Bird, S., Morales, S., Leiro, M., Kozik, Z., Crump, N.T., and Roumeliotis, T.I. (2026). EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway. Haematologica, Online ahead of print.","DOI":"10.3324\/haematol.2025.288024"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: The new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41375-026-02899-1","article-title":"CD70\/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target","volume":"40","author":"Forster","year":"2026","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-24-2668","article-title":"The CD70-CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target","volume":"31","author":"Sam","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood.2024025536","article-title":"Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells","volume":"146","author":"Kasap","year":"2025","journal-title":"Blood"},{"key":"ref_60","first-page":"890","article-title":"Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","article-title":"Limited efficacy of daratumumab in multiple myeloma with extramedullary disease","volume":"36","author":"Jelinek","year":"2022","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1046\/j.1365-2141.2001.02765.x","article-title":"Thalidomide in multiple myeloma: Lack of response of soft-tissue plasmacytomas","volume":"113","author":"Perales","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_63","first-page":"832","article-title":"Extramedullary multiple myeloma escapes the effect of thalidomide","volume":"89","author":"Cibeira","year":"2004","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2783.x","article-title":"Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration","volume":"77","author":"Cibeira","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clml.2025.03.014","article-title":"Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies","volume":"25","author":"Moreau","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1007\/s00277-025-06705-3","article-title":"Outcomes in patients with relapsed\/refractory multiple myeloma with extramedullary disease: A meta-analysis","volume":"104","author":"Voorhees","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-025-01226-8","article-title":"A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma","volume":"15","author":"Dileo","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-025-01414-6","article-title":"The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience","volume":"16","author":"Afrough","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-026-01477-z","article-title":"Real-world outcomes with elranatamab in multiple myeloma: A multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium","volume":"16","author":"Portuguese","year":"2026","journal-title":"Blood Cancer J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-026-01466-2","article-title":"Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed\/refractory multiple myeloma","volume":"16","author":"Kumar","year":"2026","journal-title":"Blood Cancer J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma","volume":"65","author":"Mol","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1200\/JCO.2026.44.16_suppl.7526","article-title":"Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up","volume":"44","author":"Lee","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Richter, J., Lee, H.C., Jagannath, S., Zonder, J.A., Hoffman, J.E., Zhou, Z.Y., Garcia-Horton, V., Fillbrunn, M., Wang, H., and Mattera, M. (2026). Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: An indirect treatment comparison. Leuk. Lymphoma, 1\u201313, ahead of print.","DOI":"10.1080\/10428194.2026.2688561"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_81","unstructured":"Afrough, A., Pasvolsky, O., Zanwar, S., Gaballa, M., Sannareddy, A., Dima, D., Goel, U., Ali, H.M., Julian, K., and Corraes, A. (2026). Impact of Extramedullary Plasmacytoma on Outcomes in Patients with Relapsed Refractory Multiple Myeloma Treated with Talquetamab: U.S. Myeloma Immunotherapy Consortium. Blood Cancer J., in press."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12325-025-03409-y","article-title":"Comparative Efficacy of Talquetamab vs. Real-World Physician\u2019s Choice of Treatment in Triple-Class-Exposed Relapsed\/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion\/MoMMent","volume":"43","author":"Einsele","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab","volume":"394","author":"Kumar","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ke, Q., and Zhou, S. (2026). Beyond dual targeting: Redefining the treatment horizon for true extramedullary myeloma?\u2014A critical appraisal. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1822293"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results","volume":"43","author":"Donk","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1200\/JCO.2025.43.16_suppl.7514","article-title":"Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed\/refractory multiple myeloma (RRMM)\u2014Dose escalation (DE) results","volume":"43","author":"Lichtman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): An updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-026-01806-6","article-title":"Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: A nationwide registry analysis","volume":"19","author":"Gagelmann","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-025-01330-9","article-title":"Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement","volume":"15","author":"Steinhardt","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis","volume":"43","author":"Jurgens","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2025030750","DOI":"10.1182\/blood.2025030750","article-title":"Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed\/refractory multiple myeloma","volume":"10","author":"Bal","year":"2026","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","article-title":"BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: A single-center, single-arm, phase 1 trial","volume":"18","author":"Yao","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"109933","DOI":"10.1016\/j.radonc.2023.109933","article-title":"Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy","volume":"189","author":"Ababneh","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1182\/bloodadvances.2024012599","article-title":"Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration","volume":"8","author":"Kostopoulos","year":"2024","journal-title":"Blood Adv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-cell immunotherapy in patients with multiple myeloma: Practical considerations from the European Myeloma Network","volume":"12","author":"Moreau","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S1470-2045(20)30234-5","article-title":"Turning up the heat on non-immunoreactive tumours: Opportunities for clinical development","volume":"21","author":"Zimmermann","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.imlet.2019.05.012","article-title":"Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide","volume":"211","author":"Yamamoto","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Zaninoni, A., Giannotta, J.A., Gall\u00ec, A., Artuso, R., Bianchi, P., Malcovati, L., Barcellini, W., and Fattizzo, B. (2021). The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.649441"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"20476","DOI":"10.18632\/oncotarget.24944","article-title":"Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation","volume":"9","author":"Fostier","year":"2018","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/cei.12343","article-title":"Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients","volume":"177","author":"Busch","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Chiu, H., Zhao, J., Basavanhally, T., Hsu, C.C., Amatangelo, M.D., Jain, G., Bjorklund, C.C., Huang, T.H., Chen, L.Y., and Milne, T.A. (2026). Mezigdomide reverses T-cell exhaustion through degradation of IKZF1\/IKZF3 and reinvigoration of cytokine production pathways. Blood, in press.","DOI":"10.1182\/blood.2025030873"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Chen, L.Y., Aleman, A., Larrayoz, M., Chiu, H., Zhao, J., Van Oekelen, O., Kelly, G., Kim-Schulze, S., Lagana, A., and Jagannath, S. (2026). Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies. Blood, in press.","DOI":"10.1182\/blood.2025030891"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood.2025029215","article-title":"An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden","volume":"146","author":"Meermeier","year":"2025","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"Shpilberg","year":"2014","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1038\/bcj.2016.4","article-title":"Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: An open-label phase I trial","volume":"6","author":"Shah","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e70213","DOI":"10.1002\/hem3.70213","article-title":"Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies","volume":"9","author":"Katodritou","year":"2025","journal-title":"Hemasphere"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood-2025-824","article-title":"Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement","volume":"146","author":"Gaballa","year":"2025","journal-title":"Blood"},{"key":"ref_127","first-page":"1","article-title":"Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement","volume":"24","author":"Derman","year":"2026","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03401.x","article-title":"Myeloma of the central nervous system: Association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations","volume":"117","author":"Fassas","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ajh.27425","article-title":"Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group","volume":"99","author":"Katodritou","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.24351","article-title":"Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clml.2024.11.010","article-title":"Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy","volume":"25","author":"Manzar","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"fcaa021","DOI":"10.1093\/braincomms\/fcaa021","article-title":"Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition","volume":"2","author":"Huehnchen","year":"2020","journal-title":"Brain Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.leukres.2006.06.019","article-title":"Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma","volume":"31","author":"Mele","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1097\/HS9.0000000000000413","article-title":"Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma","volume":"4","author":"Zajec","year":"2020","journal-title":"Hemasphere"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bjh.17717","article-title":"A nationwide survey on central nervous system multiple myeloma in Japan: Analysis of prognostic and treatment factors that impact survival","volume":"195","author":"Yamashita","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, L., Zeng, Y., Hong, R., Zu, C., Yin, E.T.S., Zhao, H., Wei, G., Yang, L., and Jin, A. (2021). Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome-A Wandering Road to Remission. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.755584"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1182\/bloodadvances.2024014345","article-title":"BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement","volume":"9","author":"Gaballa","year":"2025","journal-title":"Blood Adv."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.12404","article-title":"Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains","volume":"162","author":"Lee","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/CJI.0000000000000391","article-title":"BCMA CAR-T Therapy Is Safe and Effective for Refractory\/Relapsed Multiple Myeloma With Central Nervous System Involvement","volume":"45","author":"Wang","year":"2022","journal-title":"J. Immunother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1111\/bjh.70108","article-title":"Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort","volume":"207","author":"Noveihed","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41408-024-01185-6","article-title":"High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis","volume":"14","author":"Martello","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","article-title":"EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models","volume":"43","author":"Porazzi","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:23:22Z","timestamp":1785162202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":146,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152415"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152415","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}